Answers are grounded in this paper and cite their sources.
Type 2 diabetes mellitus is a progressive disease and this means that treatment intensification is needed to achieve glycemic goals and, for many patients, insulin will ultimately be needed. There is the potential for insulin to achieve any glycemic target, however, its initiation and up-titration is frequently delayed, partly due to the attendant weight gain and risk of hypoglycemia. Several clinical trials have demonstrated that combining a GLP-1 receptor agonist with basal insulin produces significant reductions in HbA1c without substantially increasing hypoglycemia or promoting weight gain. A once-daily coformulation of ultra-long-acting basal insulin degludec and the GLP-1 analog liraglutide, termed ‘IDegLira’, has now been developed for patients with Type 2 diabetes. Data from two Phase III clinical trials are encouraging, demonstrating marked HbA1c reductions with weight loss, low levels of hypoglycemia and limited gastrointestinal side effects. The types of patients that may benefit from a fixed-r...
No takes yet. Share an insight, caveat, or question.
Lansdown et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: